STK3

Across TCGA pan-cancer cohorts, STK3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated STK3 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher STK3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated STK3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where STK3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.972	0.091	.020	18	view →
LUAD	OS	Tertile	II,III,IV	1.000	0.852	.007	13	view →
PDAC	OS	Tertile	III,IV	0.977	0.292	.008	10	view →
GBM	DFS	Tertile	All	0.609	0.794	.022	5	view →
HNSC	DFS	Tertile	All	1.000	0.925	.025	4	view →
LSCC	DFS	Median	All	0.817	0.621	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

STK3–CCRCC (DFS)

Open the CCRCC breakdown →